- $31.59m
- $47.91m
- $80.28m
Brief: TELA Bio Q3 Revenue USD 18.957 Million Vs. IBES Estimate USD 18.9 Million
Tela Bio Inc Expected To Post A Loss Of 40 Cents A Share: Earnings Preview
Brief: Tela Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Tela Bio Announces Pricing Of Public Offering Of Common Stock And Pre-Funded Warrants
Brief: TELA Bio Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
U.S. STOCKS ON THE MOVE-Paysafe, HUYA, Oklo
U.S. STOCKS ON THE MOVE-Penumbra, Talen Energy, Paysafe
Tela Bio Slumps As Customer: targeted cyberattacks dent Q2 revenue
Tela Bio Inc Reports Results For The Quarter Ended In January: Earnings Summary
Brief: TELA Bio Q2 Revenue USD 16.091 Million Vs. IBES Estimate USD 18.5 Million
Tela Bio Inc Expected To Post A Loss Of 47 Cents A Share: Earnings Preview
Brief: TELA Bio Increased Size Of Board To Seven Members
Brief: TELA Bio Q1 Revenue USD 16.603 Million Vs. IBES Estimate USD 16.3 Million
Tela Bio Inc Expected To Post A Loss Of 50 Cents A Share: Earnings Preview
U.S. RESEARCH ROUNDUP-Darden Restaurants, Fedex, Nike
Tela Bio Inc Reports Results For The Quarter Ended In December: Earnings Summary
Brief: TELA Bio Q4 Revenue USD 16.998 Million Vs. IBES Estimate USD 16.4 Million
Brief: Tela Bio Announces U.S. Commercial Launch Of Liquifix – The Only FDA-Approved Liquid Adhesive For Internal Use In Hernia Surgery
Brief: Tela Bio Announces Sale Of Distribution Rights For Wound Care Product To Mimedx